JP2024510142A - 甲状腺眼症の処置のための方法 - Google Patents

甲状腺眼症の処置のための方法 Download PDF

Info

Publication number
JP2024510142A
JP2024510142A JP2023553957A JP2023553957A JP2024510142A JP 2024510142 A JP2024510142 A JP 2024510142A JP 2023553957 A JP2023553957 A JP 2023553957A JP 2023553957 A JP2023553957 A JP 2023553957A JP 2024510142 A JP2024510142 A JP 2024510142A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510142A5 (https=
Inventor
ダブリュー． シャーマン，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of JP2024510142A publication Critical patent/JP2024510142A/ja
Publication of JP2024510142A5 publication Critical patent/JP2024510142A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023553957A 2021-03-03 2022-03-03 甲状腺眼症の処置のための方法 Pending JP2024510142A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156320P 2021-03-03 2021-03-03
US63/156,320 2021-03-03
PCT/US2022/018737 WO2022187510A1 (en) 2021-03-03 2022-03-03 Methods for the treatment of thyroid eye disease

Publications (2)

Publication Number Publication Date
JP2024510142A true JP2024510142A (ja) 2024-03-06
JP2024510142A5 JP2024510142A5 (https=) 2025-03-11

Family

ID=83154512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553957A Pending JP2024510142A (ja) 2021-03-03 2022-03-03 甲状腺眼症の処置のための方法

Country Status (12)

Country Link
US (1) US20240158516A1 (https=)
EP (1) EP4301410A4 (https=)
JP (1) JP2024510142A (https=)
CN (1) CN117813114A (https=)
AR (1) AR125589A1 (https=)
AU (1) AU2022230416A1 (https=)
BR (1) BR112023017797A2 (https=)
CA (1) CA3210855A1 (https=)
CO (1) CO2023012639A2 (https=)
MX (1) MX2023010278A (https=)
TW (1) TW202246339A (https=)
WO (1) WO2022187510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20230406942A1 (en) * 2022-06-10 2023-12-21 Horizon Therapeutics Ireland Dac Igf1r antibodies
WO2024069236A1 (en) * 2022-09-30 2024-04-04 Horizon Therapeutics Ireland Dac Methods for treating inactive or chronic thyroid eye disease
AU2024287547A1 (en) * 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2026055673A1 (en) * 2024-09-09 2026-03-12 Viridian Therapeutics, Inc. Methods for treatment of thyroid eye disease with an anti-igf-1r antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0767959A (ja) * 1993-09-03 1995-03-14 Nissho Corp 自動注射器
JP2016528168A (ja) * 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合が無効となった抗ＩＧＦ−１Ｒ抗体及び血管性眼疾患の処置におけるそれらの使用
JP2019531705A (ja) * 2016-08-02 2019-11-07 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2013008833A (es) * 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0767959A (ja) * 1993-09-03 1995-03-14 Nissho Corp 自動注射器
JP2016528168A (ja) * 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合が無効となった抗ＩＧＦ−１Ｒ抗体及び血管性眼疾患の処置におけるそれらの使用
JP2019531705A (ja) * 2016-08-02 2019-11-07 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAHALY, GEORGE J. ET AL.: "a Novel Biologic for Active Thyroid Eye DiseaseGeorgeJ.Kahaly", ARTHRITIS & RHEUMATOLOGY, vol. 71, no. 10, JPN6026006224, 2019, pages 1807, ISSN: 0005798759 *

Also Published As

Publication number Publication date
BR112023017797A2 (pt) 2023-11-21
WO2022187510A1 (en) 2022-09-09
EP4301410A4 (en) 2025-03-26
CN117813114A (zh) 2024-04-02
TW202246339A (zh) 2022-12-01
CA3210855A1 (en) 2022-09-09
EP4301410A1 (en) 2024-01-10
CO2023012639A2 (es) 2023-10-09
MX2023010278A (es) 2023-11-21
AU2022230416A1 (en) 2023-09-28
AU2022230416A9 (en) 2024-01-25
AR125589A1 (es) 2023-08-02
US20240158516A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
US12600787B2 (en) Methods for the treatment of thyroid eye disease
US12286481B2 (en) Methods for the treatment of thyroid eye disease
JP2024510142A (ja) 甲状腺眼症の処置のための方法
US12358993B2 (en) Methods for the treatment of thyroid eye disease
US20240301072A1 (en) Methods for the treatment of thyroid eye disease
US20230270851A1 (en) Methods for the treatment of idiopathic orbital inflammation and related conditions
KR20220151619A (ko) 피부경화증 및 관련된 병태의 치료 방법
WO2022201084A1 (en) Methods for treating ocular diseases
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
US20240109970A1 (en) Methods for treating inactive thyroid eye disease
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis
PBO Adverse events included neutropenia, thrombocytopenia, elevated liver enzymes, and infections. These resolved with treatment and no patients needed to discontinue the drug due to an adverse event.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240606

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260218